|
End-of-day quote
Shenzhen S.E.
28/10/2026
|
5-day change | 1st Jan Change | ||
| 29.12 CNY | +1.22% |
|
-5.64% | -13.20% |
| 09-04 | ApicHope Pharmaceutical Obtains Approval for Sertraline Oral Solution in China | MT |
| 09-04 | ApicHope Pharmaceutical's Gout Drug Meets Primary Endpoint in Drug Trial | MT |
Company Valuation: ApicHope Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 10,200 | 9,894 | 13,394 | 7,660 | 15,065 | 13,061 | - | - |
| Change | - | -3% | 35.39% | -42.81% | 96.66% | -13.3% | - | - |
| Enterprise Value (EV) | 10,200 | 9,894 | 13,394 | 7,660 | 15,065 | 13,061 | 13,061 | 13,061 |
| Change | - | -3% | 35.39% | -42.81% | 96.66% | -13.3% | 0% | 0% |
| P/E | 33.6x | 36.2x | 71x | -14.3x | -44.9x | 25.1x | -127x | -91x |
| PBR | - | 5.12x | 5.37x | 4.1x | - | 6.93x | 7.34x | 7.98x |
| PEG | - | -3.4x | -2.1x | 0x | 1.2x | -0x | 1x | -2.3x |
| Capitalization / Revenue | - | 4.34x | 5.35x | 5.28x | - | 12.1x | 10.4x | 8.84x |
| EV / Revenue | - | 0x | 0x | 0x | - | 12.1x | 10.4x | 8.84x |
| EV / EBITDA | - | 0x | 0x | -0x | - | 14.3x | 68.7x | 69.8x |
| EV / EBIT | - | 0x | 0x | -0x | - | 19.9x | -113x | -77.3x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.1333 | 0.21 | - | - | - | - | - |
| Rate of return | - | 0.58% | 0.7% | - | - | - | - | - |
| EPS 2 | 0.7133 | 0.6373 | 0.42 | -1.196 | -0.7478 | 1.16 | -0.23 | -0.32 |
| Distribution rate | - | 20.9% | 50% | - | - | - | - | - |
| Net sales 1 | - | 2,280 | 2,503 | 1,450 | - | 1,080 | 1,258 | 1,478 |
| EBITDA 1 | - | 369.9 | 389.8 | -94.81 | - | 913 | 190 | 187 |
| EBIT 1 | - | 282 | 213.9 | -370.7 | - | 657 | -116 | -169 |
| Net income 1 | 306.9 | 290.7 | 184.6 | -540 | -337.8 | 526 | -102 | -146 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 23.93 | 23.05 | 29.83 | 17.06 | 33.55 | 29.12 | 29.12 | 29.12 |
| Nbr of stocks (in thousands) | 426,174 | 429,162 | 449,027 | 449,027 | 449,027 | 448,531 | - | - |
| Announcement Date | 20/04/22 | 19/04/23 | 26/04/24 | 24/04/25 | 23/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 25.1x | - | - | - | 1.96B | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| Average | 29.12x | 7.11x | 18.84x | 2.11% | 403.91B | |
| Weighted average by Cap. | 35.28x | 8.40x | 20.64x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 300723 Stock
- Valuation ApicHope Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
